Scancell Share Discussion Threads

[chilltime] 24/9/2024 13:19

Modi is just an extra, as big as it is.

Extras on the back of the front row of the grid called scib, a platform that she pointed out can be applied to other cancers.


A hell of a few months ahead and the direction for the front row will be decided on the level of interest POST data, not before.

Other trials falling off a cliff, Scib and Modi look like steaming ahead on efficacy proving it works.

Glymabs and Avidimab exciting the sector.

4 platforms, 4 businesses, all looking very very good. Multiple income opportunities and multiple ways to fund progress.

[marcusl2] 24/9/2024 13:17

The company that paid $1 million for exclusivity was "So excited"

[marcusl2] 24/9/2024 13:13

Scib/iScib+

"we are seeing these tumours disappear"

[chilltime] 24/9/2024 13:11

Nicking the term.

Good to get some colour on upcoming payments.

Anyone that listened would have heard the Genmab, Glymab is going into phase 1 near term and that triggers a payment.
The analysts asking won't know, they don't look at all the available presentations (sad but true) but that's the single digit millions payment.

Good to hear that the other Glymab deal is done, it just requires a Yes/No, not drawn out discussions post the pre clinical tests. 6 months being the timeline for testing which is mid December. That large Biotech was really excited about the opportunity

Then a host of others in discussions re Glymabs and Avidimab.

There is more than one angle on each Glymab so multiple deals can be done for each, depending on the speciality of interested parties.

Phase 1 Genmab, exclusive deal yes and just one other similar deal should see about $20m up front revenue without breaking into a sweat, over the next 6 months or so.

The competition in play could materially uplift the up front, after all one lot paid $200m up front for something in oncology pre clinical but shelved it due to change in strategy. Another paid something like $700m up front on something like stage 1/2.

That ignores whatever is going on with Avidimab but clearly there is a lot of interest in it.

The big players have the money, and they have the building desperation on the back of pending patent cliffs, revenue holes that Scancell therapies can fill and enhance.

[marcusl2] 24/9/2024 13:04

Doublet is so important to us.

The huge challenge with solid tumours is the TME being so hostile in cold tumours. An immune desert.

Moditope and doublet could turn them hot.

Moditope could be a game changer.

Roll on Modi-1 in Renal !

Tumors can be classified into distinct immunophenotypes based on the presence and arrangement of cytotoxic immune cells within the tumor microenvironment (TME). Hot tumors, characterized by heightened immune activity and responsiveness to immune checkpoint inhibitors (ICIs), stand in stark contrast to cold tumors, which lack immune infiltration and remain resistant to therapy. To overcome immune evasion mechanisms employed by tumor cells, novel immunologic modulators have emerged, particularly ICIs targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1/programmed death-ligand 1(PD-1/PD-L1). These agents disrupt inhibitory signals and reactivate the immune system, transforming cold tumors into hot ones and promoting effective antitumor responses.

The secretion of IFN-ϒ and the resultant inflammation could alter the nature of the TME, effectively converting “cold” tumours into “hot” ones, and so make a tumour visible to other elements of the immune system. Hence, Moditope stimulates the production of killer CD4 T cells which overcome the immune suppression induced by tumours, allowing activated T cells to seek out and kill tumour cells that would otherwise remain hidden from the immune system. This suggests Moditope offers the scope to be used alone, or in combination with other agents (including checkpoint inhibitors), to treat a wide range of currently hard to treat cancers.

[markingtime] 24/9/2024 13:03

Interesting comments on complete effects. Seemed to be growing numbers.Also some very interesting comments on the positioning in the treatment standards of care. Seem poised to compete in several segments of the patient universe.Phase 2/3 trial fully designed (330 phase 2, 200 phase 3 BUT there seems a review option after 6 months of phase 2 AND a possibility of accelerated approval at that point) and the manufacture has been completed. That study almost certain to be in USA - the EU is uncompetitively expensive.

[miavoce] 24/9/2024 13:02

Thanks Inanaco

[inanaco] 24/9/2024 13:01

with stable disease of 60%

a blast with Modi2 or CTL-4 ............

Boom

[inanaco] 24/9/2024 12:57

what i was talking about before that the "trend" = PFS

however

recap of this post


inanaco - 23 Sep 2024 - 11:23:53 - 12478 of 12543 Scancell - Pot of Gold or POS? - SCLP
Renal cell carcinoma

really simple if Modi1 works with Pd-1 and can get above 40%

v

Nivolumab alone also showed benefits in secondary outcomes with a higher objective response rate of 25% PFS 4.6 months OS 25 months

i have included PFS as the trial has been running for quite a while and this may be the trend

or above 55% ORR For doublet therapy

doublet therapy alone

The objective response rate was 42% (P<0.001), and the complete response rate was 9%

I have not included PFS as our trial has not been running long enough

[chilltime] 24/9/2024 12:56

60% is a good upgrade it was amazing at 44%.

Surely that's going in with a checkpoint then once authorised.

[inanaco] 24/9/2024 12:54

Mia

"Modi1 as monotherapy showing stable disease in 60% of patients. Bodes well for the ongoing combination cohort."

it includes single Checkpoint

[inanaco] 24/9/2024 12:52

past news was 44%

Chill ... thats increased

[inanaco] 24/9/2024 12:50

I really would not worry yourself Lozan ... "retire" take a break because when news does break your going to be violently ill as you do the maths on 1.7m

[chilltime] 24/9/2024 12:49

On the mono in ovarian in past news was very encouraging BUT subject to the possibility with checkpoints.

Todays news content seemed to hint that there are plans for a combo, so I suspect that is in discussions to allow it to go ahead. A potential partner may wish to do that considering the large void in viable therapies.

[sci102] 24/9/2024 12:46

No more questions 🤣🤣&#129315;🤣
Sure there weren't 🤣🤣&#129315;

[inanaco] 24/9/2024 12:44

Wow Modi1 is delivering with Checkpoint ............. in the hardest to treat cancers

[the real lozan] 24/9/2024 12:37

GUFFAW -
Following a dirge of a morning of an uninterupted 'flush' of backslapping that 'whitewashes' the REALITY = tumbling S P...it takes over an hour, of deep research and expertise for the WEE of Minted to come up with a response of =
"go back to Nature watch lozan
for instance"
To then list 'instances' that have NO bearing on *nature* or anything to do with the disappointing SCLP situation.
Further evidence, if needed, of FAILURE and the lack of substance from what now remains of 'Happy Clapper Central'

[inanaco] 24/9/2024 12:28

Brilliant and with Modi showing 60% SD .... wow

[rogerbridge] 24/9/2024 12:00

Logged on for the presentation.

[inanaco] 24/9/2024 11:36

go back to Nature watch lozan

for instance

Right Wing Bird watching Germany

Vultures circling ... in France

European Union puts France on notice over its spiralling debt, which now far exceeds EU rules.

[pharmaboy3] 24/9/2024 11:31

All goodHTTps://www.proactiveinvestors.co.uk/companies/news/1056766/scancell-holdings-sets-ambitious-roadmap-for-the-next-18-months-1056766.html

[the real lozan] 24/9/2024 10:35

An Alternative View / Observation.... from the REAL world -
At some stage, someone is going to 'invent' a system to CONvert the endless supply of 'utterences' of the 'happy clapper Crew' into a form... that CAN be CONdensed
And
Then spread onto the farmland....

[markingtime] 24/9/2024 10:29

Crack on then with it, Robert/JakNife :-)

[chilltime] 24/9/2024 10:24

Marcus

re

Interesting that they tested Roche`s Tecentriq (atezolizumab) with SC134.

Given the interest in it and the combo then surely Roche are all over it as part of the comment....

This data has generated broad commercial interest which will be pursued for partnership opportunities and licensing deals.